Drug intelligence / Profile preview

SHR-9539

Development stage: Phase 1
Lead developer: Shanghai Hengrui Pharmaceutical Co., Ltd.
Administration: Intravenous

Overview

SHR-9539 is a class 1 therapeutic biological product developed for the treatment of multiple myeloma. It functions by inducing and activating T cells, thereby exerting a targeted cytotoxic effect on multiple myeloma cells. The drug is currently in Phase 1 clinical trials, with studies designed to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy in patients with multiple myeloma. There are no similar drugs approved for marketing in China at this time. The developer is Shanghai Hengrui Pharmaceutical Co., Ltd., with clinical development conducted by Suzhou Suncadia Biopharmaceuticals[1][2][5][7].

Beyond the preview

Go deeper on SHR-9539.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-9539.

Explore the full profile